AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22777119 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Parenteral Nutrition (PN)
Number of subjects: 10
Study 22777119 — intervention group
Group type: COMPARATOR
Intervention: Control (Orally fed subjects)
Number of subjects: 10
Study 20537204 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency-assisted sinus excision
Number of subjects: 60
Study 20537204 — intervention group
Group type: COMPARATOR
Intervention: Cold steel sinus excision
Number of subjects: 60
Study 17520052 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in ambient sulfate particulate matter due to the copper smelter strike (60% decrease in concentrations)
Number of subjects: 0
Study 17520052 — intervention group
Group type: COMPARATOR
Intervention: Control for time trends, mortality counts in bordering states, and nationwide mortality counts for influenza/pneumonia, cardiovascular, and other respiratory deaths
Number of subjects: 0
Study 16080074 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Number of subjects: 0
Study 16080074 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 12513914 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-4 (0.5 microg/kg/day)
Number of subjects: 17
Study 12513914 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-4 (1.5 microg/kg/day)
Number of subjects: 17
Study 10344904 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7908013 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxol at doses ranging between 135 and 175 mg/m2, administered via 3-hour infusion
Number of subjects: 107
Study 7908013 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxol at doses ranging between 135 and 175 mg/m2, administered via 24-hour infusion
Number of subjects: 107
Study 7908013 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxol at higher dose levels and with prolonged infusion
Number of subjects: 107
Study 7908013 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxol
Number of subjects: 107
Study 2817461 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (TDS)
Number of subjects: 203
Study 2817461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 991548 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle acupuncture at three sites
Number of subjects: 20
Study 991548 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of isoprenaline after acupuncture
Number of subjects: 20
Study 991548 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at control sites
Number of subjects: 20
Study 991548 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture before and after histamine aerosol challenge
Number of subjects: 20
Study 30953540 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 4481
Study 30953540 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 4481
Study 30953540 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 mg and 10 mg BID)
Number of subjects: 4481
Study 28114147 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group receiving activity and sleep data at each dialysis treatment
Number of subjects: 29
Study 28114147 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 29
Study 26431646 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine granules combined with conventional treatment (oxygen uptake, nebulization, anti-infection)
Number of subjects: 60
Study 26431646 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (oxygen uptake, nebulization, anti-infection)
Number of subjects: 60
Study 23603206 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced nicotine content (RNC) cigarettes
Number of subjects: 235
Study 23603206 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg nicotine patch
Number of subjects: 235
Study 23603206 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced nicotine content (RNC) cigarettes with 21 mg nicotine patch
Number of subjects: 235
Study 23603206 — intervention group
Group type: COMPARATOR
Intervention: Control group (RNC cigarettes alone)
Number of subjects: 235
Study 21438804 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg twice daily
Number of subjects: 18113
Study 21438804 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 110 mg twice daily
Number of subjects: 18113
Study 21438804 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (both doses)
Number of subjects: 18113
Study 21438804 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18113
Study 19803568 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + YST-II
Number of subjects: 448
Study 19803568 — intervention group
Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 448
Study 16969643 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive unicondylar knee replacement with computer navigation
Number of subjects: 50
Study 14727390 — intervention group
Group type: EXPERIMENTAL
Intervention: Sport
Number of subjects: 465
Study 14727390 — intervention group
Group type: EXPERIMENTAL
Intervention: Sport Plus
Number of subjects: 465
Study 14727390 — intervention group
Group type: EXPERIMENTAL
Intervention: Sport Plus Parent
Number of subjects: 465
Study 14727390 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 465
Study 11109156 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial soap with 1.5% triclocarban
Number of subjects: 50
Study 11109156 — intervention group
Group type: COMPARATOR
Intervention: Placebo soap
Number of subjects: 50
Study 9513822 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg bid + Amoxycillin 0.5 g qid
Number of subjects: 267
Study 9513822 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg bid + Amoxycillin 0.5 g qid
Number of subjects: 267
Study 8445692 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Recording Scales
Number of subjects: 38
Study 8445692 — intervention group
Group type: COMPARATOR
Intervention: Dial scales (Control)
Number of subjects: 38
Study 3786575 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramin
Number of subjects: 25
Study 3786575 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramin
Number of subjects: 25
Study 3786575 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramin
Number of subjects: 25
Study 3786575 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 25
Study 3786575 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepin
Number of subjects: 25
Study 3786575 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 25
Study 3786575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 30157179 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) for 20 minutes
Number of subjects: 15
Study 30157179 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study 27374467 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan (200 mg/m2) and salvage ASCT
Number of subjects: 297
Study 27374467 — intervention group
Group type: COMPARATOR
Intervention: Weekly oral cyclophosphamide (400 mg/m2 per week for 12 weeks)
Number of subjects: 297
Study 27374467 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan and salvage ASCT
Number of subjects: 297
Study 27374467 — intervention group
Group type: COMPARATOR
Intervention: Weekly oral cyclophosphamide
Number of subjects: 297
Study 24679060 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical therapy plus Roux-en-Y gastric bypass
Number of subjects: 150
Study 24679060 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical therapy plus sleeve gastrectomy
Number of subjects: 150
Study 24679060 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical therapy alone
Number of subjects: 150
Study 24679060 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical groups (gastric bypass and sleeve gastrectomy)
Number of subjects: 150
Study 22710636 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-time curve technique
Number of subjects: 267
Study 22710636 — intervention group
Group type: COMPARATOR
Intervention: Minimal occlusive volume technique
Number of subjects: 267
Study 20409546 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 104
Study 20409546 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT)
Number of subjects: 104
Study 20409546 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 104
Study 17611340 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple fluid aerosol inhalation before radiotherapy
Number of subjects: 120
Study 17611340 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional oral care)
Number of subjects: 120
Study 15660805 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD programmed to DDDR with AVSH
Number of subjects: 1200
Study 15660805 — intervention group
Group type: COMPARATOR
Intervention: ICD programmed to VVI-40
Number of subjects: 1200
Study 15660805 — intervention group
Group type: COMPARATOR
Intervention: Observational arm with RV pacing > or =20%
Number of subjects: 1200
Study 11932301 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg T(3) after placebo pretreatment
Number of subjects: 18
Study 11932301 — intervention group
Group type: COMPARATOR
Intervention: Placebo after placebo pretreatment
Number of subjects: 18
Study 11932301 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg T(3) after dobutamine pretreatment
Number of subjects: 18
Study 11932301 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg T(3) after esmolol pretreatment
Number of subjects: 18
Study 10223774 — intervention group
Group type: EXPERIMENTAL
Intervention: R(+)‐ketorolac
Number of subjects: 0
Study 10223774 — intervention group
Group type: EXPERIMENTAL
Intervention: S(‐)‐ketorolac
Number of subjects: 0
Study 10223774 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ketorolac
Number of subjects: 0
Study 7599918 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 2.1 mg*kg‐1 body weight
Number of subjects: 37
Study 7599918 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 4.3 mg*kg‐1 body weight
Number of subjects: 37
Study 7599918 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 8.6 mg*kg‐1 body weight
Number of subjects: 37
Study 7599918 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (all doses)
Number of subjects: 37
Study 1692228 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate mouth swishing
Number of subjects: 40
Study 1692228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 464783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure gradient glove
Number of subjects: 15
Study 464783 — intervention group
Group type: COMPARATOR
Intervention: Control glove
Number of subjects: 15
Study 464783 — intervention group
Group type: COMPARATOR
Intervention: No glove
Number of subjects: 15
Study 31504798 — intervention group
Group type: EXPERIMENTAL
Intervention: Active screening group (annual invitation for low-dose computed tomography for 4 years)
Number of subjects: 0
Study 31504798 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 31504798 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis for active screening group
Number of subjects: 0
Study 31504798 — intervention group
Group type: COMPARATOR
Intervention: Intention-to-treat analysis for usual care (control group)
Number of subjects: 0
Study 31504798 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the smoking cessation program (specific to the scan group from one center)
Number of subjects: 0
Study 30656753 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% lotion
Number of subjects: 154
Study 30656753 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 154
Study 28213300 — intervention group
Group type: EXPERIMENTAL
Intervention: High caregiver stigma reported by caregivers (21%)
Number of subjects: 282
Study 28213300 — intervention group
Group type: EXPERIMENTAL
Intervention: Discomfort in disclosing family member's condition (45%)
Number of subjects: 282
Study 28213300 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of caregiver stigma with positive symptoms of schizophrenia
Number of subjects: 282
Study 28213300 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of caregiver stigma with higher levels of disability
Number of subjects: 282
Study 28213300 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of caregiver stigma with younger PLS age
Number of subjects: 282
Study 28213300 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of caregiver stigma with household education at secondary school level
Number of subjects: 282
Study 28213300 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative themes related to caregiver stigma
Number of subjects: 282
Study 28213300 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions suggested
Number of subjects: 282
Study 25471444 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) training
Number of subjects: 74
Study 25471444 — intervention group
Group type: COMPARATOR
Intervention: Neutral control
Number of subjects: 74
Study 22703939 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-to-moderate-intensity aerobic exercise training (CHF-AET) for 3 months
Number of subjects: 30
Study 22703939 — intervention group
Group type: COMPARATOR
Intervention: Control group (CHF-C)
Number of subjects: 30
Study 21890090 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ventricular tachycardia (VT) alone
Number of subjects: 6355
Study 21890090 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ischemia alone
Number of subjects: 6355
Study 21890090 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ischemia and VT
Number of subjects: 6355
Study 21890090 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of arrhythmia and ischemia to clinical model
Number of subjects: 6355
Study 21890090 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with both ischemia and VT
Number of subjects: 6355
Study 19218804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac troponin T (cTnT) measurement on the third morning after onset of STEMI
Number of subjects: 103
Study 15927929 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomatoes cooked with olive oil (25 ml); 470 g per meal for 5 days
Number of subjects: 23
Study 15927929 — intervention group
Group type: COMPARATOR
Intervention: Tomatoes cooked without olive oil; 470 g per meal for 5 days
Number of subjects: 23
Study 12052481 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/day)
Number of subjects: 60
Study 12052481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10333123 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus vaccine
Number of subjects: 549
Study 10333123 — intervention group
Group type: EXPERIMENTAL
Intervention: Hiberix, ActHib, Pedvax, HibTITER (Hib conjugate vaccines)
Number of subjects: 549
Study 8949976 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term therapy to improve glucose control
Number of subjects: 0
Study 8949976 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved control of hypertension
Number of subjects: 0
Study 1754753 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg twice daily for 7 days
Number of subjects: 104
Study 1754753 — intervention group
Group type: COMPARATOR
Intervention: Pivampicillin 700 mg twice daily for 7 days
Number of subjects: 104
Study 7169286 — intervention group
Group type: EXPERIMENTAL
Intervention: Food additives
Number of subjects: 0
Study 7169286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7169286 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31222796 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorzoxazone 500 mg
Number of subjects: 12
Study 31222796 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorzoxazone microdose (0.05-500 mg)
Number of subjects: 12
Study 31222796 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorzoxazone microdose (≥50 mg)
Number of subjects: 12
Study 31222796 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorzoxazone microdose
Number of subjects: 12
Study 28978240 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-abdominal guided IUD insertion
Number of subjects: 102
Study 28978240 — intervention group
Group type: COMPARATOR
Intervention: Traditional IUD insertion
Number of subjects: 102
Study 27539026 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading on a self-luminous tablet
Number of subjects: 14
Study 27539026 — intervention group
Group type: COMPARATOR
Intervention: Reading a physical book
Number of subjects: 14
Study 24773254 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (10 × 1 min at approximately 90% peak heart rate (HRpeak) with 1‐min recovery periods)
Number of subjects: 10
Study 24773254 — intervention group
Group type: EXPERIMENTAL
Intervention: CMI (30 min at approximately 65% HRpeak)
Number of subjects: 10
Study 24773254 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 10
Study 24773254 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 10
Study 24773254 — intervention group
Group type: EXPERIMENTAL
Intervention: CMI
Number of subjects: 10
Study 23015562 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing (MB) total knee replacement
Number of subjects: 42
Study 23015562 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing (FB) total knee replacement
Number of subjects: 42
Study 19320869 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHP)
Number of subjects: 116
Study 19320869 — intervention group
Group type: COMPARATOR
Intervention: Artesunate-amodiaquine (AAQ)
Number of subjects: 116
Study 17650790 — intervention group
Group type: EXPERIMENTAL
Intervention: Guben Yiliu II (GY II) combined with arterial perfusion with chemotherapeutic agent
Number of subjects: 65
Study 17650790 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapeutic agent alone
Number of subjects: 65
Study 14738236 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure for 2 hours at ambient levels (PM10 108 microg x m(‐3))
Number of subjects: 0
Study 12204321 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 49
Study 12204321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 9695720 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole once daily for 4 days
Number of subjects: 10
Study 9695720 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 10
Study 7866915 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of oral calcium
Number of subjects: 9
Study 7866915 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU of intranasal calcitonin
Number of subjects: 9
Study 7866915 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control session)
Number of subjects: 9
Study 2547245 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin for three months in addition to conventional local therapy (N=18)
Number of subjects: 26
Study 2547245 — intervention group
Group type: COMPARATOR
Intervention: Conventional local therapy (Control group, N=8)
Number of subjects: 26
Study 577494 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training using written words (based on Terrace's errorless discrimination model and Premack's language training)
Number of subjects: 3
Study 31549413 — intervention group
Group type: EXPERIMENTAL
Intervention: Care bundle group
Number of subjects: 300
Study 31549413 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 31549413 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency department compliance
Number of subjects: 300
Study 31549413 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetic department compliance
Number of subjects: 300
Study 31549413 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthogeriatrics compliance
Number of subjects: 300
Study 31514425 — intervention group
Group type: EXPERIMENTAL
Intervention: aL procedure
Number of subjects: 44
Study 28053158 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioengineered bilayered living cellular construct (BLCC) skin substitute together with standard of care (compression therapy)
Number of subjects: 0
Study 28053158 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (compression therapy)
Number of subjects: 0
Study 25727741 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 22)
Number of subjects: 41
Study 25727741 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 41
Study 23763822 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 72
Study 23763822 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 72
Study 23763822 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 72
Study 21457668 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alpha-lipoic acid (ALA) 1200 mg/day for 8 weeks
Number of subjects: 103
Study 21457668 — intervention group
Group type: COMPARATOR
Intervention: Placebo 1200 mg/day for 8 weeks
Number of subjects: 103
Study 18222683 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol Turbuhaler
Number of subjects: 77
Study 18222683 — intervention group
Group type: COMPARATOR
Intervention: Formoterol pMDI+S (control)
Number of subjects: 77
Study 16517331 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P - preoperative placebo tablet, propofol induction, propofol-air/O2 maintenance
Number of subjects: 150
Study 16517331 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I + O - preoperative 8-mg ondansetron tablet, thiopental induction, isoflurane-N2O maintenance
Number of subjects: 150